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ABSTRACT
Objectives To report clinical implementation of cell-free
DNA (cfDNA) analysis of maternal blood in screening for
trisomies 21, 18 and 13 in twin pregnancies and examine
variables that could influence the failure rate of the test.
Methods cfDNA testing was performed in 515 twin
pregnancies at 10–28 weeks’ gestation. The failure rate of
the test to provide results was compared with that in 1847
singleton pregnancies, and logistic regression analysis was
used to determine which factors among maternal and
pregnancy characteristics were significant predictors of
test failure.
Results Failure rate of the cfDNA test at first sampling
was 1.7% in singletons and 5.6% in twins. Of those
with a test result, the median fetal fraction in twins was
8.7% (range, 4.1–30.0%), which was lower than that
in singletons (11.7% (range, 4.0–38.9%)). Multivariable
regression analysis demonstrated that twin pregnancy,
higher maternal weight and conception by in-vitro
fertilization provided significant independent prediction
of test failure. Follow-up was available in 351 (68.2%)
of the twin pregnancies and comprised 334 with euploid
fetuses, 12 discordant for trisomy 21 and five discordant
for trisomy 18. In all 323 euploid cases with a result, the
risk score for each trisomy was< 1:10 000. In 11 of the
12 cases with trisomy 21 and in the five with trisomy 18,
the cfDNA test gave a high-risk result, but in one case of
trisomy 21, the score was< 1:10 000.
Conclusion In twin pregnancies screening by cfDNA
testing is feasible, but the failure rate is higher and
detection rate may be lower than in singletons. Copyright
© 2014 ISUOG. Published by John Wiley & Sons Ltd.
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INTRODUCTION
In singleton pregnancies, cell-free DNA (cfDNA) ana-
lysis of maternal blood provides effective screening
for trisomies 21, 18 and 13 with respective detec-
tion rates of about 99%, 97% and 92%, at a
combined false-positive rate (FPR) of 0.4%1. Such
high performance of screening has been reported
for both high-risk pregnancies and in the general
population1–5.
The incidence of multiple pregnancy has increased
worldwide, mainly owing to the increased use of assisted
reproductive techniques and the increasing maternal age
of the population6–8. Both the risk for aneuploidies and
the risk of miscarriage from invasive testing are higher in
twin pregnancies than in singletons9,10. It would therefore
be useful if cfDNA testing could be used for effective
screening in twins. However, in twin pregnancies cfDNA
testing is more complex than in singleton pregnancies
because in dizygotic twins only one fetus is likely to have
aneuploidy when detected, and the contribution of cfDNA
of the two fetuses into the maternal circulation can vary by
nearly two-fold11,12. Consequently, if the fetal fraction of
the affected fetus is below the threshold of 4% necessary
for successful cfDNA analysis, but there is a high contribu-
tion from the normal cotwin, so that the total fetal fraction
is satisfactory, the wrong conclusion can be reached – that
the pregnancy is not trisomic. To avoid this potential
mistake, it has been proposed that, in cfDNA testing
in twin pregnancies, the lower fetal fraction of the two
fetuses, rather than the total, should be used in the assess-
ment of risk for aneuploidies13. However, an inevitable
consequence of such a policy is that the no-result
rate in twins is likely to be higher than in singleton
pregnancies14.
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The objective of this study was to report the
clinical implementation of cfDNA analysis of maternal
blood in screening for trisomies 21, 18 and 13
in a large series of twin pregnancies and examine
variables that could influence the failure rate of
the test.
SUBJECTS AND METHODS
In this prospective multicenter study, 515 twin pregnan-
cies underwent screening for trisomies 21, 18 and 13 by
cfDNA testing at 10–28 weeks’ gestation between May
2013 and September 2014. All patients received detailed
pretest counseling and provided written informed consent
for the test. Maternal blood was obtained by venepunc-
ture (20 mL, in Streck cfDNA BCT™ tubes) and sent
via courier to the USA for chromosome-selective cfDNA
testing (Harmony™ Prenatal Test, Ariosa Diagnostics,
Inc., San Jose, CA, USA)13–15. The information given
to the laboratory for each sample was patient-unique
identifier, maternal age, method of conception and date
of blood collection. Risk scores for each trisomy were
provided as a percentage with ranges capped at> 99%
and<0.01%.
The failure rate of the cfDNA test to provide results was
compared with that in prospectively collected samples
from 1847 singleton pregnancies undergoing cfDNA
testing between January 2013 and September 2014, at
the department of Obstetrics and Gynecology, University
Hospital Brugmann, Brussels, Belgium, at which all data
from the participating centers were collated in a unique
database. The study was approved by the local ethics
committee.
Statistical analysis
In cases with a cfDNA test result, the median of the lower
fetal fraction of twin pregnancies was compared with
the corresponding median in singleton pregnancies using
the Mann–Whitney U-test. In the whole population of
singleton and twin pregnancies, regression analysis was
used to investigate the effect on test failure rate at first
sampling of twin pregnancy (yes/no), maternal smoking
status (smoker/non-smoker), method of conception
(in-vitro fertilization (IVF)/non-IVF) and origin of oocyte
(mother/donor), as categorical variables and maternal
weight (kg) and gestational age at test (weeks), as
continuous numerical variables. In twin pregnancies,
regression analysis was used to investigate the effect on
test failure rate of maternal smoking status, method of
conception, origin of oocyte and chorionicity (monochori-
onic/dichorionic) as categorical variables and maternal
weight and gestational age as continuous numerical
variables.
Data were analyzed with the statistical software
SPSS version 16.0 (SPSS Inc., Chicago, IL, USA), and
Excel version 9.0 (Microsoft, Redmond, WA, USA).
Two-sided P<0.05 was considered to be statistically
significant.
RESULTS
Study population
In total, 1847 singleton and 515 twin pregnancies
underwent cfDNA testing either because prior screening
by the first-trimester combined test or second-trimester
triple/quadruple biochemistry test or ultrasound examina-
tion identified them as being at high risk for fetal trisomy
or the women wanted to have the new test as a primary
method of screening. The median maternal age was 36.8
(range, 19.0–50.3) years and the median maternal weight
was 64.4 (range, 42.0–148.0) kg. The test was performed
at a median gestational age of 13.6 (range, 10.0–34.7)
weeks for singletons and 13.0 (range, 10.0–28.0) weeks
for twins; the gestational age was< 14 weeks in 1027
(55.6%) of the singletons and in 353 (68.5%) of the
twins. Conception was by IVF in 189 (10.2%) of the
singletons and in 272 (52.8%) of the twin pregnancies.
Fetal fraction
The median of the lower fetal fraction in twin pregnancies
was 8.7% (range, 4.1–30.0%), which was lower than the
corresponding median in singleton pregnancies (11.7%
(range, 4.0–38.9%)) (P< 0.001). In the cases tested
before 14 weeks’ gestation, the median of the lower
fetal fraction in twins was 8.6% (range, 4.1–30.0%) and
the median fetal fraction in singletons was 11.3% (range,
4.0–38.9%) (P< 0.001).
No result from cfDNA testing
The cfDNA test failed to provide results in the first sample
obtained from patients in 32 (1.7%) singletons and in
29 (5.6%) twins (Figure 1). In the cases tested before 14
weeks’ gestation, the cfDNA test did not provide results in
22 (2.1%) of the singletons and in 16 (4.5%) of the twins.
Univariable regression analysis demonstrated that
significant predictors of failure of the test were twin
pregnancy, higher maternal weight and conception by
IVF, but not gestational age at test, cigarette smoking
or origin of oocyte. Multivariable regression analysis
demonstrated that significant independent predictors of
test failure were twin pregnancy, higher maternal weight
and conception by IVF (Table 1 and Figure 2). In twin
pregnancies, univariable regression analysis demonstrated
that significant predictors of failure of the test were
higher maternal weight and conception by IVF, but
not gestational age at test, cigarette smoking, origin of
oocyte or chorionicity. Multivariable regression analysis
demonstrated that significant independent predictors of
test failure were higher maternal weight and conception
by IVF (Table 2).
In 26 of the 29 twin pregnancies in which the first
sample did not provide a result from cfDNA testing, a
second sample was examined and a result was obtained
in 13 (50.0%). In singleton pregnancies, the test was
repeated in 28 of the 32 cases with a failed first sample
and a result was obtained in 19 (67.9%).
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Figure 1 Flowcharts of prospective screening for trisomies 21, 18 and 13 by cell-free DNA (cfDNA) testing of maternal blood for
aneuploidies in twin (a) and singleton (b) pregnancies.
Table 1 Regression analysis in prediction of effect of different variables on failure of cell-free DNA testing for aneuploidies in twin and
singleton pregnancy (n=2362)
Univariable analysis Multivariable analysis
Variable Value Odds ratio (95% CI) P Odds ratio (95% CI) P
Twin pregnancy
Yes 515 (21.8) 3.384 (2.028–5.650) < 0.001 2.331 (1.245–4.362) 0.008
No 1847 (78.2) 1 1
Maternal smoker*
Yes 91 (3.9) 1.362 (0.417–4.448) 0.609
No 2130 (90.2) 1
Maternal weight (kg)† 64.4 (42.0–148.0) 1.049 (1.034–1.065) < 0.001 1.057 (1.040–1.075) <0.001
Gestational age at test (weeks) 13.6 (10.0–34.7) 0.954 (0.876–1.041) 0.284
Method of conception
IVF 461 (19.5) 4.496 (2.692–7.508) < 0.001 3.781 (2.025–7.057) <0.001
Non-IVF 1901 (80.5) 1 1
Origin of oocyte
Mother 2303 (97.5) 1
Donor 59 (2.5) 2.074 (0.631–6.819) 0.230
Data given as n (%) or median (range). *Data available for 2221 (94.0%) patients. †Data available for 2296 (97.2%) patients. IVF, in-vitro
fertilization.
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Figure 2 Relationship of maternal and pregnancy characteristics (pregnancy status (a), mode of conception (b) and maternal weight (c)) with
failure of cell-free DNA (cfDNA) testing of maternal blood for aneuploidies. IVF, in-vitro fertilization.
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Table 2 Regression analysis in prediction of effect of different variables on failure rate of cell-free DNA testing for aneuploidies in twin
pregnancy (n= 515)
Univariable analysis Multivariable analysis
Variable Value Odds ratio (95% CI) P Odds ratio (95% CI) P
Maternal smoker*
Yes 19 (3.7) 1.871 (0.405–8.642) 0.422
No 355 (68.9) 1
Maternal weight (kg)† 64.0 (43.9–117.0) 1.058 (1.028–1.090) <0.001 1.064 (1.031–1.097) <0.001
Gestational age at test (weeks) 13.0 (10.0–28.0) 0.918 (0.886–1.143) 0.918
Method of conception
IVF 272 (52.8) 2.967 (1.244–7.074) <0.014 3.557 (1.372–9.217) <0.01
Non-IVF 243 (47.2) 1 1
Origin of oocyte
Mother 467 (90.7) 1
Donor 48 (9.3) 0.709 (0.163–3.076) 0.646
Chorionicity‡
Monochorionic 67 (13.0) 1
Dichorionic 301 (58.4) 2.313 (0.527–10.145) 0.266
Data given as n (%) or median (range). *Data available for 374 (72.6%) patients. †Data available for 449 (87.2%) patients. ‡Data available
for 368 (71.5%) patients. IVF, in-vitro fertilization.
Pregnancy outcome in twins and performance of the
cfDNA test
Outcomes were divided into (1) normal if the karyotype of
chorionic villi, amniotic fluid or neonatal blood was nor-
mal or the neonate was phenotypically normal (n=334);
(2) trisomies 21, 18 or 13 if the karyotype of chorionic
villi, amniotic fluid or neonatal blood demonstrated the
relevant trisomy (12 cases discordant for trisomy 21 and
five discordant for trisomy 18); (3) unknown karyotype
because the pregnancy resulted in miscarriage or still-
birth and no karyotyping of fetal tissue was carried out
(n= 7); and (4) outcome unknown because the pregnan-
cies were continuing (n= 19) or were lost to follow-up
(n= 138).
cfDNA testing provided risk scores after first or second
sampling in 340 (96.9%) of the 351 twin pregnancies
with known outcome. In the 323 euploid cases in which
a cfDNA test result was obtained, the risk score for each
trisomy was< 1:10 000. In 11 of the 12 cases with trisomy
21 and in the five with trisomy 18, the cfDNA test gave
a high-risk result, but in one case of trisomy 21 the score
was< 1:10 000.
DISCUSSION
Main findings of the study
This prospective study demonstrates the feasibility of
chromosome-selective sequencing of cfDNA in maternal
blood for the assessment of risk for fetal trisomies 21, 18
and 13 in twin pregnancies. In twins, the rate of reporting
results from cfDNA testing was 94.4%, which improved
to 96.9% after repeat sampling, and in those with results
the median of the lower fetal fraction was 8.7%. These
rates were lower than the respective values of 98.3%
and 99.3% observed in singleton pregnancies, in which
the median fetal fraction was 11.7%. The reason for the
lower reporting rate in twins was low fetal fraction, which
is the inevitable consequence of selecting the lower fetal
fraction of the two fetuses, rather than the total fetal
fraction, in estimating the risk for aneuploidies1. The
rationale for this choice is to avoid a false-negative result
in a dizygotic twin pregnancy discordant for aneuploidy,
for which the total fetal fraction is satisfactory but the
contribution of the affected fetus could be less than 4%.
In twins, the cfDNA test did not provide any
false-positive results and it detected 16 of the 17
pregnancies discordant for trisomy 21 or 18. However,
many of the pregnancies were continuing or were lost to
follow-up and therefore the study cannot provide accurate
assessment of detection rate.
Significant predictors of failure of the cfDNA test
to provide results are high maternal weight and IVF
conception, which was by far more common in the twin
than in the singleton pregnancies (53% vs 10%). Although
the failure rate was twice as high in dichorionic than in
monochorionic twins, this difference was not significant.
The likely source of fetal cfDNA in maternal plasma is
dying cells in the placenta, and the inverse association
between fetal fraction and maternal weight could be
attributed to a dilutional effect16–18. Another possible
explanation for such an association is that, in obese
women, there is an accelerated turnover of adipocytes,
which releases an increased amount of cfDNA of maternal
origin into the circulation, hence relatively less fetal
cfDNA19,20.
The finding of lower fetal fraction in IVF conceptions
may be the consequence of a smaller placental mass and
lower number of apoptotic cells than in natural concep-
tions. We have previously reported significant associations
between fetal fraction and serum pregnancy-associated
plasma protein-A (PAPP-A) and free β-human chorionic
gonadotropin, whose concentration provides an indirect
measure of placental mass17,18,20. Evidence for impaired
placentation in IVF conceptions is provided by reports
Copyright © 2014 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2015; 45: 61–66.
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that in such pregnancies the serum concentration of
PAPP-A is decreased by 10–25%21–23 and the incidence
of pre-eclampsia is increased24.
Limitations of the study
The main limitations of the study relate to the small
number of trisomic pregnancies and the lack of data on
pregnancy outcome in about one third of the cases, which
prevents definitive conclusions from being drawn as to
the performance of screening by cfDNA testing through
chromosome-selective sequencing in twins.
Comparison with previous studies
There are four previous studies on screening for trisomies
by cfDNA testing in twin pregnancies. In three studies,
massively parallel shotgun sequencing was used to
examine stored plasma or prospectively collected blood
from a combined total of 226 twin pregnancies25–27.
In these studies, no attempt was made to determine the
fetal fraction for each twin and it was assumed that
the contribution from each fetus to the maternal plasma
cfDNA was adequate for accurate results. There were
206 cases with euploid fetuses, 15 discordant and two
concordant for trisomy 21, two discordant for trisomy
18 and one discordant for trisomy 13. The cfDNA test
provided results for all cases and correctly classified all
cases except one of the cases of trisomy 18, which was
reported as normal. Therefore, the detection rate for all
trisomies was 95.0% (19 of 20), with an FPR of 0%.
One previous study used chromosome-selective
sequencing and an algorithm that relied on the lower fetal
fraction of the twins, as in the present study, to assess
the risk for trisomies in stored plasma samples obtained
at 11–13 weeks’ gestation from 207 twin pregnancies14.
Risk scores for trisomies 21, 18 and 13 by cfDNA testing
were provided for 192 (92.8%) cases, including 181 with
euploid fetuses, 10 discordant for trisomy 21 and one
discordant for trisomy 13. The test correctly identified
nine of the 10 cases of trisomy 21 and the one case of
trisomy 13 with no false-positive results14.
In the cumulative data from the literature and the
present study on cfDNA testing, in a total of 758 twin
pregnancies with known outcome, comprising 710 with
euploid fetuses, 39 with trisomy 21, seven with trisomy
18 and two with trisomy 13, the respective detection rates
for the trisomies were 95%, 86% and 100%, at an FPR
of 0%.
Conclusions
There are sufficient data to suggest that with cfDNA
testing for trisomies in twin pregnancies, firstly, the FPR
is very low, as in singletons, secondly, the detection rate is
high, albeit the total number of affected cases is too small
for accurate conclusions to be drawn, and thirdly, the
method of estimating the fetal fraction from each twin and
ensuring that the lower of the two is at least 4%, aiming
to minimize the risk of providing false-negative results, is
associated with a higher failure rate than methods that
ignore assessment of the contribution of each fetus to the
maternal cfDNA concentration.
In twin pregnancies, the rate of failure to obtain results
from cfDNA testing increases with maternal weight, as in
singleton pregnancies, and is higher in IVF than in natural
conceptions.
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